Cargando…
Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents
BACKGROUND: Studies on temporal changes in noninvasive fibrosis indices and liver stiffness measurement (LSM) in patients with chronic hepatitis C (CHC) treated with direct-acting antiviral agents (DAAs) are limited. METHODS: We retrospectively enrolled consecutive patients with CHC who had received...
Autores principales: | Hsu, Wei-Fan, Lai, Hsueh-Chou, Su, Wen-Pang, Lin, Chia-Hsin, Chuang, Po-Heng, Chen, Sheng-Hung, Chen, Hung-Yao, Wang, Hung-Wei, Huang, Guan-Tarn, Peng, Cheng-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486982/ https://www.ncbi.nlm.nih.gov/pubmed/31029101 http://dx.doi.org/10.1186/s12876-019-0973-5 |
Ejemplares similares
-
New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis
por: Wang, Hung-Wei, et al.
Publicado: (2017) -
Publisher Correction: New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis
por: Wang, Hung-Wei, et al.
Publicado: (2018) -
Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C
por: Chen, Sheng-Hung, et al.
Publicado: (2018) -
Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B
por: Peng, Cheng-Yuan, et al.
Publicado: (2017) -
On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma
por: Wang, Hung-Wei, et al.
Publicado: (2020)